Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors
AssigneeThe General Hospital Corporation
InventorsAnthony Rosenzweig, Wei Chao
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating or preventing cardiac disorders such as heart failure, by administering to a mammal a therapeutically effective amount of an FADD inhibitor. According to the present invention, the FADD inhibitor is anti-apoptotic, anti-inflammatory, or both. Also disclosed are screening methods that make use of FADD for the identification of novel therapeutics for treating or preventing cardiac disorders.
Claims23
1-14. (canceled)
A method for treating, reducing, or preventing a cardiac disorder in a mammal, said method comprising administering to said mammal an effective amount of FADD or an anti-inflammatory FADD inhibitor.
17-19. (canceled)
22-28. (canceled)
A human cardiomyocyte expressing a dominant negative FADD protein.
A human cardiomyocyte expressing a recombinant FADD protein.
31-41. (canceled)
A method for identifying a candidate compound for treating, reducing, or preventing cardiac inflammation in a mammal, said method comprising:
- (a) contacting a cardiomyocyte expressing a FADD gene with a candidate compound;
- and
- (b) measuring FADD gene expression or FADD protein activity in said a cardiomyocyte, a candidate compound that reduces said expression or said activity, relative to FADD expression or activity in a cardiomyocyte not contacted with said candidate compound, identifying said candidate compound as a candidate compound useful for treating, reducing, or preventing cardiac inflammation.
43-44. (canceled)
A method for identifying a candidate compound for treating, reducing, or preventing a cardiac disorder, said method comprising:
- (a) contacting a cardiomyocyte expressing a FADD gene with a candidate compound;
- and
- (b) measuring FADD gene expression or FADD protein activity in said a cardiomyocyte, a candidate compound that reduces said expression or said activity, relative to FADD expression or activity in a cardiomyocyte not contacted with said candidate compound, identifying said candidate compound as a candidate compound useful for treating, reducing, or preventing said cardiac disorder.
(canceled)
A method for identifying a candidate compound for treating, reducing, or preventing cardiac inflammation, said method comprising:
- (a) contacting FADD protein with a candidate compound;
- and
- (b) determining whether said candidate compound binds said FADD protein, a candidate compound that binds said FADD protein being a candidate compound useful for treating, reducing, or preventing cardiac inflammation.
52-53. (canceled)
A method for identifying a candidate compound for treating, reducing, or preventing cardiac disorder, said method comprising:
- (a) contacting FADD protein with a candidate compound;
- and
- (b) determining whether said candidate compound binds said FADD protein, a candidate compound that binds said FADD protein being a candidate compound useful for treating, reducing, or preventing said cardiac disorder.
56-64. (canceled)
Dependencies are inferred from the claim text.